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produce a peak within 1–2 °C of the predicted Tm. This
allows Tm peaks, which indicate the presence or absence
of a PCR product, to be strategically placed within the
typical melting curve range of 45–70 °C for hybridization
probes. Over this melting curve range we feel it should be
possible to clearly distinguish three peaks in a single
channel. This potentially makes it possible to multiplex
six mutations in two capillaries when both fluorescent
channels are used. This enhances the capabilities of the
LightCycler for mutation detection; similar strategies
could also be used for other real-time systems.
The results presented here demonstrate the ability to
carry out multiplex mutation detection by use of a com-
bination of ARMS PCR and real-time detection. A labora-
tory currently using ARMS PCR in a diagnostic setting
can quite easily convert the standard ARMS PCR to a
real-time ARMS PCR. This could have a major advantage
in time savings and reduce the handling of potential
carcinogenic ethidium bromide.
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Large-scale human genetic studies require new technolo-
gies to genotype several samples with relative ease, high
accuracy, and reasonable costs. Among the available
approaches, a microelectronic array technology has been
developed for DNA hybridization analysis of mutations/
single-nucleotide polymorphisms (SNPs) (1–4). The mi-
croelectronic array system (NanoChip® Molecular Biol-
ogy Workstation; Nanogen) produces a defined electric
field that allows charged molecules, such as nucleic acids,
to be transported to any test site, or pad, on the electronic
chip (NanoChip cartridge). Electronic-based molecule ad-
dressing can rapidly achieve a high concentration of
amplicons on each pad of the cartridge. Control of tem-
perature allows use of an optimal thermal stringency to
characterize a SNP/mutation in all 100 pads of a cartridge
simultaneously (5, 6). A thin hydrogel permeation layer
overlies the pads; the presence of avidin or streptavidin
in this layer allows the binding of biotinylated PCR
products.
Although the technology is attractive, only a few pro-
tocols for its use have been published (7–11). We describe
the development, optimization, and validation of a high-
throughput method for SNPs and mutations analysis that
allows performance of 1372 characterizations on each
chip.
We studied samples from 150 individuals for 14 SNPs/
mutations previously characterized by standard methods
(restriction analysis, automatic sequencing, and allelic
discrimination). Genomic DNA was isolated from periph-
eral blood by use of the FlexiGene DNA reagent set
(QIAGEN GmbH). We analyzed 14 DNA mutations/
SNPs for a total of 2100 characterizations (homozygous
wild type, n  1367; heterozygous, n  522; homozygous
mutant, n  211). The 14 nucleotide substitutions were
SNPs/mutations involving the glycoprotein Ia (GpIa),
glycoprotein IIIa (GpIIIa), follicle-stimulating hormone
receptor (FSHR), hereditary hemochromatosis (HFE), and
1 chain of collagen type 6 (COL6A1) genes.
For each mutation/SNP we designed a set of probes
consisting of a forward and a reverse PCR oligonucleotide
(one oligonucleotide for each SNP/mutation was 5	-
biotinylated); two reporter oligonucleotides (one labeled
with Cy3, specific for the wild-type nucleotide; the other,
labeled with Cy5, specific for the mutant nucleotide), and
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one stabilizer oligonucleotide. Reporter oligonucleotides
had Cy3 or Cy5 fluorophore at the 5	 end and a SNP/
mutation at the 3	 end. The stabilizer was located imme-
diately downstream from the 3	 end of reporter oligonu-
cleotides. All of the designed oligonucleotides are listed in
Table A of the Data Supplement that accompanies the
online version of this Technical Brief at http://www.
clinchem.org/content/vol50/issue4/.
To genotype the 14 SNPs/mutations, we amplified
seven DNA sequences by PCR. The seven amplicons were
pooled and desalted with the Nucleo Fast system (96-well
PCR plates) from Macherey-Nagel. We mixed 30 L of
each 55-L desalted amplicon pool with 30 L of 100
mmol/L histidine. Four wells containing solutions of 0.3
mol/L NaOH, 0.1 mol/L NaOH, and 50 mmol/L histi-
dine and a known heterozygous sample for each SNP/
mutation analyzed were also included on the plate. The
loader was programmed to electronically address each
amplicon pool to specific pads on the cartridge. The 50
mmol/L histidine solution without amplicons was ad-
dressed to two pads in each cartridge as background.
Each pool of samples was analyzed on one pad in two
different cartridges, whereas two known heterozygous
samples for each mutation/SNP were addressed to four
pads in each cartridge. Each sample was amplified in a
second independent PCR reaction, pooled, and addressed
to one pad of a third cartridge. A second amplification
reaction was also carried out for the two known heterozy-
gous samples for each mutation/SNP, which were pooled
and addressed to four pads of the third cartridge.
One set of stabilizer and reporter oligonucleotides at a
time, specific for one SNP/mutation, was hybridized to
the cartridge. The hybridization mixture was then re-
moved, and the chip was rinsed twice with high-salt
buffer. The cartridge was then placed in the reader, where
the temperature was increased to the optimum tempera-
ture for discrimination (see Table A of the online Data
Supplement). After each hybridization and scanning pro-
cedure, a stripping step was performed to remove report-
ers and to allow hybridization with another set of probes.
The same protocol was applied to analyze each mutation/
SNP. To study all 14 SNPs/mutations, we performed 14
hybridization/stripping steps. A fluorescence scan was
performed with the system reader. The software directly
assigned the genotype to each sample (Table 1). Known
heterozygous control samples were used as Cy3:Cy5
fluorophore ratio references for signal normalization. For
background subtraction, fluorescence signals in the histi-
dine pads were used. The mean values for Cy3 and Cy5
fluorescence were determined by averaging the amount
of fluorescence in each pad. The Cy5:Cy3 ratio for each
pad in the heterozygous control set was averaged to-
gether to build the scale. The scaled mean was determined
by multiplying the scale and the mean. The ratios of the
scaled means were used to make the genotype designa-
tion. For this purpose the Nanogen-recommended criteria
were used: heterozygous if the Cy5:Cy3 ratio was be-
tween 3:1 and 1:3; homozygous for the wild-type and
mutant alleles if the ratios were 1:5 and 5:1, respec-
tively. Ratios between 1:3 and 1:5 for the wild-type or
between 3:1 and 5:1 for the mutant alleles indicated a need
to repeat the analysis. For pad exclusion, the signal-to-
noise ratio was set to a default at 5:1.
Fluorescence intensities were similar for the same PCR
products addressed to different pads of the same car-
tridge and in different pads of a different cartridge. Major
differences in signal intensities were observed in the case
of the second amplification addressed to a different car-
tridge. After the normalization procedure, all heterozy-
gous samples showed ratios very close to 1, ranging from
1.0 to 1.53 [mean (SD), 1.11 (0.13)] in adherence with data
relative to the known heterozygous samples shown in
Table B of the online Data Supplement.
No background increase was detected after the 14th
hybridization. The background signal ranged from 1.5 to
15 independent of the SNP/mutation analyzed and was
not related to the number of hybridization/stripping
steps performed.
We found 100% concordance between the results ob-
tained by the approach described here and those obtained
by standard techniques (automated sequencing, allelic
discrimination, and restriction analysis) either within or
between assays. This concordance was observed for all of
the samples independent of the genotype (homozygous
wild type, 1367 of 1367; heterozygous, 522 of 522; ho-
mozygous mutant, 211 of 211), the SNPs/mutations stud-
Table 1. Example of all data generated by the analysis software for a heterozygous, a homozygous wild-type, and a
homozygous mutant sample.a
a R, red (Cy5 fluorescence); G, green (Cy3 fluorescence); SNR, signal-to-noise ratio.
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ied, and the comparison method. In 7% of the samples the
signal-to-noise ratio was low. The software failed to
assign a genotype because of a PCR failure in 5% of
samples and because of an insufficient amount of PCR
product in 2% of samples.
Our data are in agreement with other reports on the
Nanogen technology (7, 9, 10), but our approach reduced
the time for the detection of a SNP/mutation from 5 min
(manufacturer’s protocol) to 0.7 min. The manufactur-
er’s protocol required 8 h for loading of 98 PCR products,
one hybridization step, one washing step, and 98 detec-
tions. The longest time (7 h) was required to address the
98 samples to the pads. Our protocol took 7 h for the
addressing of 98 samples, each containing 7 amplicons,
and 8 h to perform 14 hybridizations, 14 washing steps,
and 14  98 detections. An additional factor to be consid-
ered is the cost per assay: reagents in the protocol sug-
gested by the manufacturer cost approximately €9 for
each detection (DNA extraction, PCR, purification, chip,
and probes). The simultaneous analysis of multiple
SNPs/mutations on each pad provided by our protocol
reduces the price to approximately €2 for each SNP/
mutation. This reagent cost is similar to or less expensive
than the reagent costs for the standard techniques (allelic
discrimination, restriction analysis, and sequencing), with
reagent cost ranges of €2–25. In addition, the shorter
analysis time for our protocol reduces technician time and
provides increased numbers of results over which to
amortize the cost of the instrument. Finally, our protocol
allows optimization of procedures in only 1 h for each
SNP/mutation.
To the best of our knowledge, this is the first report
describing the multiple analysis of 14 SNPs/mutations
involving 5 human genes (7 amplicons) on each pad of the
same microelectronic chip without affecting the accuracy
of the analysis.
The easy preparation and analysis of samples, the low
cost per sample, the reduction in the time required for the
analysis, and the concordance of the results with the
comparison methods demonstrate that this approach im-
proves the throughput of microelectronic chip technol-
ogy. We believe that the Nanogen technology is a prom-
ising tool for molecular diagnosis, pharmacogenetics, and
research.
We thank Dr. Bjo¨rn Hihn for assistance during this study.
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